PUBLISHER: TechNavio | PRODUCT CODE: 1602031
PUBLISHER: TechNavio | PRODUCT CODE: 1602031
Irritable Bowel Syndrome Market 2024-2028
The irritable bowel syndrome market is forecasted to grow by USD 1931.9 mn during 2023-2028, accelerating at a CAGR of 9.3% during the forecast period. The report on the irritable bowel syndrome market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing prevalence of ibs, growing awareness and diagnosis of ibs, and rising global healthcare expenditure.
Market Scope | |
---|---|
Base Year | 2024 |
End Year | 2028 |
Series Year | 2024-2028 |
Growth Momentum | Accelerate |
YOY 2024 | 9% |
CAGR | 9.3% |
Incremental Value | $1931.9 mn |
Technavio's irritable bowel syndrome market is segmented as below:
By Type
By Drug Class
By Geographical Landscape
This study identifies the increasing number of drug approvals as one of the prime reasons driving the irritable bowel syndrome market growth during the next few years. Also, partnerships and collaborations among vendors and exploration of amitriptyline as treatment for ibs will lead to sizable demand in the market.
The report on the irritable bowel syndrome market covers the following areas:
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading irritable bowel syndrome market vendors that include Abbott Laboratories, AbbVie Inc., Alfasigma Spa, Astellas Pharma Inc., AstraZeneca Plc, Bausch Health Companies Inc., Bayer AG, Boehringer Ingelheim International GmbH, GlaxoSmithKline Plc, Ironwood Pharmaceuticals Inc, Johnson and Johnson Services Inc., Mallinckrodt Plc, Nestle Health Science S.A., Novartis AG, Pfizer Inc., RedHill Biopharma Ltd., Sanofi SA, Sebela Pharmaceuticals Inc., Takeda Pharmaceutical Co. Ltd., and Teva Pharmaceutical Industries Ltd.. Also, the irritable bowel syndrome market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Exhibits: